SCHEMBL2117699

SCHEMBL2117699

ON=C(Cl)c1ccc(Cl)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 2/20 0.42
KCNQ2 O43526 2/20 0.42
KCNE1 P15382 2/20 0.42
KCNQ1 P51787 2/20 0.42
KCNQ5 Q9NR82 1/20 0.41
MAOB P27338 5/20 0.37
SLC6A4 P31645 1/20 0.37
IDO1 P14902 2/20 0.34
S1PR1 P21453 1/20 0.33
S1PR3 Q99500 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
KDR P35968 1/20 0.33
TSHR P16473 2/20 0.33
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5798393 1.00 KCNQ3 (0.42) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL5799965 0.84 KCNQ3 (0.42) KCNQ3KCNQ2KCNE1KCNQ1MAOB
SCHEMBL5799966 0.84 KCNQ3 (0.42) KCNQ3KCNQ2KCNE1KCNQ1MAOB
SCHEMBL2476170 0.83 CES2 (0.50) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL2476167 0.83 CES2 (0.50) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL8249580 0.83 CES2 (0.50) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL11774103 0.81 TSHR (0.50) TSHRMAPT
SCHEMBL5798624 0.81 TSHR (0.50) TSHRMAPT
SCHEMBL5798622 0.81 TSHR (0.50) TSHRMAPT
SCHEMBL22394813 0.78 KDM1A (0.45) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095002-A1 ISOXAZOLE-5-CARBOXAMIDE DERIVATIVES N.V. ORGANON (NL) 2012-04-19 US disclosed
EP-2393788-A1 ISOXAZOLE-5-CARBOXAMIDE DERIVATIVES N.V. Organon (NL) 2011-12-14 EP disclosed
WO-2010089297-A1 ISOXAZOLE-5-CARBOXAMIDE DERIVATIVES N.V. ORGANON (NL) 2010-08-12 WO disclosed
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
WO-2006039667-A2 WATER-BASED DELIVERY SYSTEMS COLLAGENEX PHARMACEUTICALS, INC. (US) 2006-04-13 WO disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095002-A1 ISOXAZOLE-5-CARBOXAMIDE DERIVATIVES TRPV1, TRPV5, P2RX5 KCNQ3 180/4885KCNQ2 206/4885KCNE1 441/4885
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR KCNQ3 1778/4885KCNQ2 2934/4885KCNE1 1910/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 KCNQ3 2191/4885KCNQ2 2565/4885KCNE1 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.